List of Excipients in Branded Drug LEVOCARNITINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	LEVOCARNITINE	levocarnitine	50383-171	CHERRY
Akorn	LEVOCARNITINE	levocarnitine	50383-171	MALIC ACID
Akorn	LEVOCARNITINE	levocarnitine	50383-171	METHYLPARABEN
Akorn	LEVOCARNITINE	levocarnitine	50383-171	PROPYLPARABEN
Akorn	LEVOCARNITINE	levocarnitine	50383-171	SUCROSE
Akorn	LEVOCARNITINE	levocarnitine	50383-171	WATER

Generic Drugs Containing LEVOCARNITINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	levocarnitine	0143-9852	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	levocarnitine	0143-9852	SODIUM HYDROXIDE
American Regent Inc	levocarnitine	0517-1045	HYDROCHLORIC ACID
American Regent Inc	levocarnitine	0517-1045	SODIUM HYDROXIDE
American Regent Inc	levocarnitine	0517-1045	WATER
Rising Pharma Holdings Inc	levocarnitine	16571-762	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in LEVOCARNITINE?

# Of NDCs	Excipient
2	ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE
3	CHERRY
4	HYDROCHLORIC ACID
2	MAGNESIUM STEARATE
4	MALIC ACID

Levocarnitine Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Levocarnitine is a mature, largely generic drug with limited core-molecule exclusivity and substantial formulation opportunity. The strongest commercial positions are pediatric oral liquids, dialysis-compatible products, preservative-free hospital injections, high-concentration dosing formats, and differentiated taste-masked products. Excipient selection should address dose volume, palatability, microbial control, renal and metabolic comorbidities, container compatibility, and manufacturing cost.

What is the FDA regulatory status of levocarnitine?

Levocarnitine, also known as L-carnitine, is FDA-approved for the treatment of primary and secondary carnitine deficiency. Approved dosage forms include oral tablets, oral solutions, and intravenous injections. The reference product is Carnitor, marketed in multiple presentations over time by manufacturers associated with the levocarnitine franchise.[1]

Product type	Representative strength	Primary commercial use
Oral tablet	330 mg	Chronic outpatient therapy
Oral solution	1 g/10 mL, or 100 mg/mL	Pediatric, geriatric, dysphagia, and dose-flexible therapy
Injection	200 mg/mL	Hospital, dialysis, and acute replacement settings

Levocarnitine is also widely sold as a dietary supplement. Supplement products do not have the same FDA approval, manufacturing, labeling, clinical-evidence, or postmarket requirements as prescription levocarnitine products. A commercial strategy must keep the prescription-drug and supplement pathways separate.

The prescription market is driven by diagnosed carnitine deficiency, metabolic disorders, dialysis-associated depletion, and selected off-label uses. Product differentiation is therefore more likely to come from usability and administration economics than from a new therapeutic mechanism.

What excipients are used in levocarnitine oral solutions?

Representative levocarnitine oral solutions use a relatively conventional excipient system. Public product labeling identifies excipient classes such as purified water, acidulants, preservatives, sweeteners, and flavors.[1,2]

A typical oral-solution architecture includes:

Excipient function	Common candidate	Formulation purpose
Vehicle	Purified water	Solubilizes levocarnitine and supports dose measurement
pH control	Citric acid or citrate buffer	Controls chemical stability and taste
Preservative	Methylparaben and propylparaben	Controls microbial growth in multidose packaging
Sweetener	Sodium saccharin or another intense sweetener	Reduces bitterness and acidic taste
Flavor	Fruit or medicinal flavor system	Improves pediatric adherence
Chelation or stabilization	Product-specific	May limit trace-metal-driven degradation
Viscosity modifier	Product-specific	Improves mouthfeel and dose retention

Levocarnitine is highly water-soluble, so a conventional aqueous solution is technically straightforward. The principal development problem is organoleptic performance. The molecule has a strong, salty, fish-like or amine-associated taste that can reduce adherence, particularly in children receiving repeated daily doses.

How should the oral-solution excipient system be optimized?

The best development sequence is:

1. Establish the target concentration and maximum daily dose.
2. Define the allowable dose volume for pediatric and adult use.
3. Screen pH and buffer systems.
4. Evaluate sweetener and flavor combinations in the presence of the full levocarnitine dose.
5. Select preservative or preservative-free packaging.
6. Confirm extractables, leachables, microbial limits, and stability in the proposed container.

At 100 mg/mL, a 2-g daily dose requires 20 mL of solution. A higher-concentration product could reduce dose volume, but concentration increases may affect taste, osmolality, viscosity, crystallization risk, and administration tolerability.

A sugar-free product is commercially attractive because many patients with metabolic disorders, diabetes, renal disease, or long-term treatment needs may benefit from avoiding sucrose and glucose. Artificial sweeteners can provide low-calorie performance, but the formulation must account for aftertaste and pediatric acceptability.

Polyols such as sorbitol or glycerol can improve mouthfeel but may create gastrointestinal tolerance issues at high daily doses. This is particularly relevant because levocarnitine itself can cause gastrointestinal adverse effects, including nausea, vomiting, abdominal cramps, and diarrhea.[1] A formulation that improves taste but increases osmotic gastrointestinal burden may reduce net adherence.

What excipient strategy is best for pediatric levocarnitine?

Pediatric oral liquid is the most defensible formulation opportunity. Primary carnitine deficiency and inherited metabolic disorders can require chronic administration in infants and children, where dose flexibility and palatability are central product attributes.

A pediatric formulation should prioritize:

• Sugar-free composition
• Low dose volume
• Reliable oral syringe compatibility
• Taste masking without excessive sweetness
• Low viscosity for accurate withdrawal
• Preservative control
• Flexible dosing increments
• Compatibility with feeding tubes when clinically appropriate
• Packaging that limits dosing errors

A 100 mg/mL solution is commercially familiar, but a more concentrated product could reduce administration burden. The development tradeoff is straightforward:

Design	Advantage	Risk
100 mg/mL solution	Familiar concentration and easier dose calculation	Larger dose volume
200 mg/mL solution	Lower administration volume	Greater taste intensity and higher formulation burden
Oral suspension	Potential taste-masking flexibility	Dose uniformity and resuspension risk
Powder for reconstitution	Lower shipping weight and potentially longer shelf life	Reconstitution errors and added preparation steps
Unit-dose liquid	Better hygiene and dosing control	Higher packaging cost

A multidose bottle with a calibrated oral syringe is likely to offer the best balance between cost and usability. Unit-dose packaging may be justified for hospitals, home-care programs, or patients with high contamination risk, but its cost is harder to support in a low-price generic market.

Which excipients create regulatory or patient-safety risks?

Excipient selection should reflect the patient population rather than rely on generic oral-liquid conventions.

Preservatives

Methylparaben and propylparaben are established pharmaceutical preservatives, but preservative-free packaging may offer a stronger hospital and pediatric positioning. A preservative-free product could use:

• Unit-dose ampoules
• Blow-fill-seal packaging
• Aseptic multidose systems
• Metered-dose oral dispensers
• Smaller fill volumes

The commercial value depends on whether the sponsor can demonstrate a meaningful clinical, handling, or institutional benefit.

Sodium-containing excipients

Sodium saccharin contributes limited sodium compared with the active ingredient dose, but the full formulation should be assessed for patients with renal disease, dialysis dependence, hypertension, or sodium restrictions. Sodium content should be disclosed clearly in labeling where clinically relevant.

Sugar and polyols

Sucrose-based formulations may be less attractive for long-term use. Sorbitol, mannitol, and glycerol can create gastrointestinal effects and should be evaluated at the maximum daily dose rather than at the nominal formulation concentration.

Alcohol and propylene glycol

Alcohol and propylene glycol should generally be avoided or minimized in products intended for neonates and young children unless the clinical need is clear and the exposure is justified. These excipients can create age-dependent safety and labeling issues.

Allergens and flavor systems

Flavor systems should avoid unnecessary allergen exposure and should be screened for interactions with preservatives, packaging, and pH. A medicinal flavor may perform better than an aggressive fruit flavor when the active ingredient has a persistent aftertaste.

What formulations are protected by levocarnitine patents?

Levocarnitine has no apparent modern composition-of-matter barrier comparable with a newly launched small molecule. The active ingredient has been used clinically for decades, and multiple manufacturers market generic or multisource products.

The most relevant intellectual-property opportunities are formulation-specific:

Potential IP area	Commercial relevance	Patent strength
Taste-masked oral solution	Pediatric adherence and repeat dosing	Moderate if supported by comparative data
High-concentration solution	Lower dose volume	Moderate, subject to obviousness and enablement
Preservative-free multidose package	Pediatric and hospital positioning	Moderate if packaging and microbiological performance are demonstrated
Unit-dose delivery system	Dosing accuracy and contamination control	Moderate
Stable powder for reconstitution	Distribution and shelf-life benefits	Moderate
Novel flavor or sweetener system	Consumer and pediatric differentiation	Usually weak unless technically unexpected
New therapeutic method	Depends on clinical evidence and claim scope	Variable
Manufacturing process	Cost, impurity control, and scale-up	Moderate if process-specific and non-obvious

Excipient patents are rarely strong when they claim routine substitutions without unexpected technical effects. A defensible patent package should link the excipient choice to measurable performance, such as improved taste scores, reduced dose volume, longer stability, lower preservative exposure, improved tube compatibility, or reduced dosing error.

What is the Orange Book status of levocarnitine?

Levocarnitine is a legacy prescription product with generic competition and limited evidence of commercially important current Orange Book patent protection. The principal risk for a new entrant is therefore regulatory execution and price competition rather than a core patent blocking generic entry.

A sponsor should distinguish among:

• The reference NDA and its listed presentations
• Approved ANDAs
• Any listed patents or exclusivity codes
• Product-specific labeling differences
• Patent certifications submitted with an ANDA
• Litigation filed after a Paragraph IV notice

For a mature product such as levocarnitine, a Paragraph IV challenge would generally target a formulation, method-of-use, or packaging patent rather than the active ingredient itself. A generic sponsor with a simple immediate-release tablet or conventional oral solution would typically face a lower patent burden than a sponsor pursuing a novel high-concentration or taste-masked presentation.

Because Orange Book entries and approval status can change, the relevant commercial diligence is presentation-specific. A patent listed against an oral solution would not necessarily affect a tablet, injection, or separate delivery system.[3]

When does levocarnitine lose exclusivity?

Core levocarnitine exclusivity expired long ago. The product is now positioned in the mature-generic phase, with competition centered on manufacturing cost, supply reliability, dosage-form availability, and institutional contracting.

Exclusivity category	Current commercial implication
Active-ingredient exclusivity	No practical barrier
Original product exclusivity	Expired
Orphan exclusivity	Not a current broad barrier to routine generic supply
Formulation patents	Potentially relevant only for specific differentiated products
Method-of-use patents	Relevant only to narrow claimed uses
Regulatory exclusivity for a new formulation	Possible if a qualifying new drug product is approved

A sponsor should not assume that an excipient innovation automatically creates meaningful market exclusivity. To support a durable position, the product would need a combination of patent claims, regulatory differentiation, physician adoption, and channel-specific value.

How strong is the levocarnitine patent estate?

The patent estate is weak for the active ingredient and potentially moderate for narrow formulation or delivery claims.

Patent strength increases when the product has:

• A non-obvious excipient combination
• Comparative taste or adherence data
• Improved chemical or microbiological stability
• Reduced dose volume at equivalent bioavailability
• A documented advantage in enteral-tube delivery
• A specialized container-closure system
• Manufacturing-process advantages that are difficult to design around

Patent strength decreases when claims cover:

• Routine flavor substitution
• Standard sweeteners
• Conventional preservatives
• Broad pH ranges without unexpected results
• Generic oral-liquid compositions
• Unclaimed commercial features

For a new entrant, trade secrets may provide more value than patents in flavor systems, impurity control, preservative optimization, and high-throughput filling. Trade-secret protection is particularly relevant where competitors can design around a narrow excipient claim.

Which companies are competing in levocarnitine?

The market includes the reference-brand franchise, generic pharmaceutical manufacturers, hospital suppliers, and supplement companies. Prescription competition is primarily multisource generic competition.

The competitive landscape can be segmented as follows:

Segment	Differentiation basis
Generic tablets	Lowest cost, established supply
Generic oral solutions	Concentration, bottle size, taste, syringe compatibility
Branded or specialty oral liquids	Pediatric support and formulation quality
Injectable products	Sterility, supply reliability, hospital contracts
Dialysis-focused supply	Administration workflow and institutional availability
Dietary supplements	Retail distribution, flavor, dosage variety, consumer branding

A sponsor seeking premium pricing should avoid entering only with another conventional tablet. The more attractive route is a clinically useful oral liquid or hospital product with a clear administration benefit.

What manufacturing and excipient barriers affect commercial entry?

Manufacturing barriers are manageable but still material in a low-margin market.

Oral liquids

Critical controls include:

• Assay and content uniformity
• pH drift
• Preservative effectiveness
• Flavor reproducibility
• Microbial control
• Container compatibility
• Fill-volume accuracy
• Stability after opening

High-dose oral liquids can impose substantial raw-material and packaging costs. Flavor systems may also create supply-chain dependence on specialist vendors.

Sterile injections

Injectable levocarnitine requires validated aseptic processing or terminal sterilization where feasible, suitable container-closure integrity, particulate control, endotoxin control, and a robust supply chain for sterile manufacturing. Hospital buyers may value shortage prevention more than small formulation differences.

Packaging

Packaging can create a meaningful commercial advantage. Options include:

• Child-resistant bottles with oral syringes
• Unit-dose cups
• Ampoules
• Blow-fill-seal containers
• Prefilled oral dispensers
• Tamper-evident multidose systems

The selected package should be evaluated with caregivers, pharmacists, and institutional users. A technically elegant formulation can fail commercially if the dose is difficult to measure or the bottle is difficult to use.

What generic launch risks exist for levocarnitine?

Generic launch risk is concentrated in price erosion, limited market size, and product commoditization.

Risk	Impact	Mitigation
Multiple generic suppliers	Rapid price compression	Differentiate by dosage form or service
Small patient population	Limited scale	Target specialty pharmacies and metabolic centers
Taste-related nonadherence	Low refill persistence	Conduct sensory optimization
Supply interruptions	Lost institutional contracts	Dual-source critical excipients
Low-cost incumbent liquids	Difficult premium pricing	Reduce dose volume or improve packaging
Complex sterile manufacturing	Delayed launch	Use established contract manufacturing capacity
Supplement competition	Consumer confusion	Maintain prescription-specific clinical positioning

A conventional tablet launch has the highest risk of immediate price competition. An oral solution with superior palatability and dosing tools may achieve better retention, but it requires clinical and commercial evidence.

What licensing deals could support a levocarnitine product?

Licensing opportunities are more likely to involve technology than the active ingredient. Relevant counterparties include:

• Taste-masking technology providers
• Oral-liquid contract development and manufacturing organizations
• Metered-dose oral-delivery companies
• Pediatric packaging suppliers
• Specialty-pharmacy networks
• Metabolic-disease commercial partners
• Sterile injectable manufacturers

A licensing transaction is most defensible when the partner contributes a protected delivery system, validated pediatric usability data, or manufacturing capacity that materially reduces time to approval.

An active-ingredient license alone is unlikely to create a strong strategic position because levocarnitine is widely available and chemically uncomplicated. The commercial value lies in the finished product, regulatory file, supply reliability, and prescriber access.

How does levocarnitine compare with competing carnitine products?

Levocarnitine competes with racemic or non-prescription carnitine products in some markets, but the prescription product has a clearer regulatory basis for treating documented deficiency.

Attribute	Prescription levocarnitine	Dietary L-carnitine supplement
Regulatory status	FDA-approved drug for defined indications	Food/supplement pathway
Quality requirements	Drug cGMP and approved specifications	Dietary supplement requirements
Dosing precision	Controlled product labeling	Variable by product
Clinical positioning	Deficiency treatment	General wellness and sports nutrition
Reimbursement	Potential prescription coverage	Usually cash-pay
Commercial buyer	Health systems, pharmacies, specialty channels	Retail and online consumers

The supplement market can create brand awareness but may also pressure pricing. A prescription product should emphasize dose precision, validated manufacturing, pediatric usability, and medical supervision.

What is the revenue exposure and commercial upside?

Levocarnitine is unlikely to support a large premium-drug revenue model without a differentiated platform. The commercial upside is strongest in focused niches:

1. Pediatric oral solution.
2. High-concentration, low-volume liquid.
3. Preservative-free unit-dose liquid.
4. Dialysis and hospital injection supply.
5. Specialty-pharmacy adherence programs.
6. Tube-compatible formulations.
7. Contract manufacturing for regional markets.

Revenue exposure depends on payer coverage, diagnosis volume, generic price levels, and the number of competing suppliers. Publicly comparable revenue figures are not consistently disclosed across private-label, generic, and supplement channels. A business case should therefore use bottom-up assumptions based on treated patients, annual dose, net price, channel discounts, and refill persistence rather than rely on a single market-size estimate.

Key Takeaways

• Levocarnitine is a mature generic drug with no meaningful active-ingredient patent barrier.
• Oral liquids offer the strongest formulation opportunity.
• Pediatric taste masking, sugar-free composition, lower dose volume, and dosing accuracy are commercially relevant.
• Preservative-free and unit-dose formats may support hospital and specialty positioning.
• Conventional excipient substitutions are unlikely to produce strong patent protection without comparative technical data.
• Trade secrets may be more valuable than patents for flavor systems and manufacturing controls.
• Generic launch risk is driven by price erosion, limited patient volume, supply reliability, and incumbent products.
• A differentiated oral solution or reliable sterile injectable is more attractive than another undifferentiated tablet.
• Prescription levocarnitine and dietary supplements should be treated as separate regulatory and commercial markets.

FAQs

Is levocarnitine oral solution suitable for pediatric patients?

Yes. Oral solution is the most flexible dosage form for pediatric dosing, but taste, dose volume, preservative exposure, and accurate oral-syringe delivery are central development considerations.

Can a high-concentration levocarnitine solution obtain patent protection?

Potentially, but concentration alone is usually insufficient. Patent strength improves when the formulation demonstrates unexpected stability, palatability, reduced dose volume, or improved administration performance.

Is preservative-free levocarnitine commercially attractive?

It can be attractive for pediatric and institutional markets, particularly when paired with unit-dose or aseptic packaging. The benefit must offset higher packaging and manufacturing costs.

Does levocarnitine require a biosimilar strategy?

No. Levocarnitine is a small-molecule drug, not a biologic. Competition proceeds through generic-drug pathways rather than biosimilar approval.

What is the most defensible commercial position for a new levocarnitine entrant?

A low-volume, sugar-free, taste-masked oral solution with a calibrated delivery device and reliable specialty-pharmacy supply is the strongest general position. A preservative-free hospital injection is a separate opportunity for manufacturers with sterile capacity.

References

1. U.S. Food and Drug Administration. (n.d.). Carnitor (levocarnitine) prescribing information. FDA-approved labeling.

2. DailyMed. (n.d.). Levocarnitine oral solution prescribing information. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.